The Experts below are selected from a list of 44313 Experts worldwide ranked by ideXlab platform
Sheng Fei Oon - One of the best experts on this subject based on the ideXlab platform.
-
Biomarker Research in prostate cancer—towards utility, not futility
Nature reviews. Urology, 2011Co-Authors: Sheng Fei Oon, Stephen R. Pennington, John M. Fitzpatrick, R. William G. WatsonAbstract:The identification of an appropriate clinical question is critical for any Biomarker project. Despite rapid advances in technology, few Biomarkers have been forthcoming for prostate cancer. This could be because the clinical questions under investigation have not actually originated from clinical practice. These clinical questions are difficult to identify in the complex and heterogeneous pathogenesis of prostate cancer. In this Review, we have developed a prostate cancer 'roadmap' to identify the aspects of prostate cancer that may be amenable to Biomarker discovery and serve as a guide for future projects in prostate cancer Biomarker Research.
-
Biomarker Research in prostate cancer towards utility not futility
Nature Reviews Urology, 2011Co-Authors: Sheng Fei Oon, Stephen R. Pennington, John M. Fitzpatrick, William R G WatsonAbstract:The identification of an appropriate clinical question is critical for any Biomarker project. Despite rapid advances in technology, few Biomarkers have been forthcoming for prostate cancer. This could be because the clinical questions under investigation have not actually originated from clinical practice. These clinical questions are difficult to identify in the complex and heterogeneous pathogenesis of prostate cancer. In this Review, we have developed a prostate cancer 'roadmap' to identify the aspects of prostate cancer that may be amenable to Biomarker discovery and serve as a guide for future projects in prostate cancer Biomarker Research.
William R G Watson - One of the best experts on this subject based on the ideXlab platform.
-
Biomarker Research in prostate cancer towards utility not futility
Nature Reviews Urology, 2011Co-Authors: Sheng Fei Oon, Stephen R. Pennington, John M. Fitzpatrick, William R G WatsonAbstract:The identification of an appropriate clinical question is critical for any Biomarker project. Despite rapid advances in technology, few Biomarkers have been forthcoming for prostate cancer. This could be because the clinical questions under investigation have not actually originated from clinical practice. These clinical questions are difficult to identify in the complex and heterogeneous pathogenesis of prostate cancer. In this Review, we have developed a prostate cancer 'roadmap' to identify the aspects of prostate cancer that may be amenable to Biomarker discovery and serve as a guide for future projects in prostate cancer Biomarker Research.
R. William G. Watson - One of the best experts on this subject based on the ideXlab platform.
-
Biomarker Research in prostate cancer—towards utility, not futility
Nature reviews. Urology, 2011Co-Authors: Sheng Fei Oon, Stephen R. Pennington, John M. Fitzpatrick, R. William G. WatsonAbstract:The identification of an appropriate clinical question is critical for any Biomarker project. Despite rapid advances in technology, few Biomarkers have been forthcoming for prostate cancer. This could be because the clinical questions under investigation have not actually originated from clinical practice. These clinical questions are difficult to identify in the complex and heterogeneous pathogenesis of prostate cancer. In this Review, we have developed a prostate cancer 'roadmap' to identify the aspects of prostate cancer that may be amenable to Biomarker discovery and serve as a guide for future projects in prostate cancer Biomarker Research.
Stephen R. Pennington - One of the best experts on this subject based on the ideXlab platform.
-
Biomarker Research in prostate cancer—towards utility, not futility
Nature reviews. Urology, 2011Co-Authors: Sheng Fei Oon, Stephen R. Pennington, John M. Fitzpatrick, R. William G. WatsonAbstract:The identification of an appropriate clinical question is critical for any Biomarker project. Despite rapid advances in technology, few Biomarkers have been forthcoming for prostate cancer. This could be because the clinical questions under investigation have not actually originated from clinical practice. These clinical questions are difficult to identify in the complex and heterogeneous pathogenesis of prostate cancer. In this Review, we have developed a prostate cancer 'roadmap' to identify the aspects of prostate cancer that may be amenable to Biomarker discovery and serve as a guide for future projects in prostate cancer Biomarker Research.
-
Biomarker Research in prostate cancer towards utility not futility
Nature Reviews Urology, 2011Co-Authors: Sheng Fei Oon, Stephen R. Pennington, John M. Fitzpatrick, William R G WatsonAbstract:The identification of an appropriate clinical question is critical for any Biomarker project. Despite rapid advances in technology, few Biomarkers have been forthcoming for prostate cancer. This could be because the clinical questions under investigation have not actually originated from clinical practice. These clinical questions are difficult to identify in the complex and heterogeneous pathogenesis of prostate cancer. In this Review, we have developed a prostate cancer 'roadmap' to identify the aspects of prostate cancer that may be amenable to Biomarker discovery and serve as a guide for future projects in prostate cancer Biomarker Research.
John M. Fitzpatrick - One of the best experts on this subject based on the ideXlab platform.
-
Biomarker Research in prostate cancer—towards utility, not futility
Nature reviews. Urology, 2011Co-Authors: Sheng Fei Oon, Stephen R. Pennington, John M. Fitzpatrick, R. William G. WatsonAbstract:The identification of an appropriate clinical question is critical for any Biomarker project. Despite rapid advances in technology, few Biomarkers have been forthcoming for prostate cancer. This could be because the clinical questions under investigation have not actually originated from clinical practice. These clinical questions are difficult to identify in the complex and heterogeneous pathogenesis of prostate cancer. In this Review, we have developed a prostate cancer 'roadmap' to identify the aspects of prostate cancer that may be amenable to Biomarker discovery and serve as a guide for future projects in prostate cancer Biomarker Research.
-
Biomarker Research in prostate cancer towards utility not futility
Nature Reviews Urology, 2011Co-Authors: Sheng Fei Oon, Stephen R. Pennington, John M. Fitzpatrick, William R G WatsonAbstract:The identification of an appropriate clinical question is critical for any Biomarker project. Despite rapid advances in technology, few Biomarkers have been forthcoming for prostate cancer. This could be because the clinical questions under investigation have not actually originated from clinical practice. These clinical questions are difficult to identify in the complex and heterogeneous pathogenesis of prostate cancer. In this Review, we have developed a prostate cancer 'roadmap' to identify the aspects of prostate cancer that may be amenable to Biomarker discovery and serve as a guide for future projects in prostate cancer Biomarker Research.